ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decrease in Short Interest

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) saw a significant drop in short interest in the month of October. As of October 31st, there was short interest totalling 7,840,000 shares, a drop of 18.2% from the October 15th total of 9,590,000 shares. Currently, 25.9% of the company's stock are sold short. Based on an average daily volume of 701,400 shares, the days-to-cover ratio is presently 11.2 days.

Analysts Set New Price Targets

ALXO has been the subject of a number of analyst reports. Lifesci Capital cut ALX Oncology from a "strong-buy" rating to a "hold" rating in a report on Wednesday, July 31st. Stifel Nicolaus reaffirmed a "hold" rating and issued a $3.00 price objective (down previously from $5.00) on shares of ALX Oncology in a report on Friday, August 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of ALX Oncology in a research report on Tuesday. UBS Group lowered their price target on ALX Oncology from $25.00 to $4.00 and set a "buy" rating on the stock in a research report on Friday, August 16th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $25.00 price objective on shares of ALX Oncology in a research note on Tuesday, August 13th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $12.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. CANADA LIFE ASSURANCE Co acquired a new stake in ALX Oncology during the 1st quarter worth approximately $27,000. EntryPoint Capital LLC acquired a new position in shares of ALX Oncology during the first quarter worth about $32,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in ALX Oncology by 394.8% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,517 shares of the company's stock valued at $39,000 after acquiring an additional 5,200 shares in the last quarter. Hsbc Holdings PLC acquired a new stake in ALX Oncology in the 2nd quarter valued at about $63,000. Finally, AQR Capital Management LLC increased its position in ALX Oncology by 50.7% during the second quarter. AQR Capital Management LLC now owns 18,079 shares of the company's stock worth $109,000 after buying an additional 6,080 shares during the last quarter. Institutional investors own 97.97% of the company's stock.

ALX Oncology Stock Performance

ALXO traded down $0.06 during trading on Friday, reaching $1.28. 294,713 shares of the company's stock were exchanged, compared to its average volume of 777,672. The company has a quick ratio of 4.82, a current ratio of 4.82 and a debt-to-equity ratio of 0.07. The company has a market capitalization of $67.25 million, a P/E ratio of -0.45 and a beta of 1.03. ALX Oncology has a fifty-two week low of $1.26 and a fifty-two week high of $17.83. The business has a 50 day moving average price of $1.70 and a 200 day moving average price of $5.68.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.